Dahuang Huanglian Xiexin Decoction Ameliorates Obesity by Targeting the PPARγ/STAT3/PTGS2 Axis: Integrative Network Pharmacology and Experimental Validation
Chemistry & Biodiversity · 2026
DOI: 10.1002/cbdv.202501831 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2026. Verfasst von Huan Gu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Cardiology, China-Japan Friendship Hospital, Beijing, P. R. China. Hauptthemen laut MEDLINE: Obesity, Drugs, Chinese Herbal, PPAR gamma, STAT3 Transcription Factor. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CACMS Innovation Fund, China Center for Evidence-Based Traditional Chinese Medicine.
Abstract (Originalsprache)
Childhood obesity is a major preventable health issue. This study evaluated the anti‐obesity effects of Dahuang Huanglian Xiexin Decoction (DHXD) and explored its potential mechanisms using network pharmacology and molecular docking. Active compounds and targets of DHXD were identified from TCMSP and HERB databases, while obesity‐related targets were obtained from GeneCards, TTD, and DisGeNET. A protein‐protein interaction network helped identify 45 shared targets and 10 hub genes. Molecular docking confirmed strong binding between DHXD components and key targets. An obesity rat model was established using a high‐fat diet, followed by DHXD treatment. Parameters such as body weight, fat mass, and rectal temperature were monitored. Biochemical assays and histological staining assessed metabolic and tissue changes. Western blotting evaluated the expression of obesity‐related proteins. Results showed DHXD significantly reduced body weight and fat accumulation, improved blood glucose and lipid profiles, and promoted lipolysis and browning of white adipose tissue. Molecular analysis highlighted PPARγ, PTGS2, and STAT3 as central targets mediating DHXD's anti‐obesity effects. These findings support the potential of DHXD as an effective therapeutic agent against obesity and provide insights into its molecular mechanism of action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Integrative Cardiology, China-Japan Friendship Hospital, Beijing, P. R. China.
- Graduate School, Nanjing University of Chinese Medicine, Nanjing, P. R. China.
- Department of Pediatrics, Beijing Fangshan District Liangxiang Hospital, Beijing, P. R. China.
- Department of Pediatrics, Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing, P. R. China.
ORCID-Profile: Ji Li
Förderung
- CACMS Innovation Fund
- China Center for Evidence-Based Traditional Chinese Medicine
Zitieren
APA
Gu, H., Yang, L., Hao, L., Li, M., & Li, J. (2026). Dahuang Huanglian Xiexin Decoction Ameliorates Obesity by Targeting the PPARγ/STAT3/PTGS2 Axis: Integrative Network Pharmacology and Experimental Validation. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202501831
Vancouver
Gu H, Yang L, Hao L, Li M, Li J. Dahuang Huanglian Xiexin Decoction Ameliorates Obesity by Targeting the PPARγ/STAT3/PTGS2 Axis: Integrative Network Pharmacology and Experimental Validation. Chemistry & Biodiversity. 2026. doi:10.1002/cbdv.202501831
BibTeX
@article{Gu2026,
author = {Gu, Huan and Yang, Lichang and Hao, Long and Li, Mingxi and Li, Ji},
title = {Dahuang Huanglian Xiexin Decoction Ameliorates Obesity by Targeting the PPARγ/STAT3/PTGS2 Axis: Integrative Network Pharmacology and Experimental Validation},
journal = {Chemistry & Biodiversity},
year = {2026},
doi = {10.1002/cbdv.202501831}
}
EUVIMED